Innovate Biopharmaceuticals, Inc. Announces First Patient Dosed in the First Phase 3 Clinical Trial for Patients with Celiac Disease
August 13, 2019 09:00 ET
|
Innovate Biopharmaceuticals, Inc
CeD LA 3001 trial doses first patient in historic Phase 3 celiac disease trial RALEIGH, N.C., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a...
Innovate Biopharmaceuticals Reports Second Quarter 2019 Results and Corporate Updates
August 08, 2019 16:30 ET
|
Innovate Biopharmaceuticals, Inc
Company is exploring potential strategic opportunities and non-dilutive sources of capital, and partnerships Continued activities of the first Phase 3 clinical trial for celiac disease including the...
Innovate Biopharmaceuticals Announces Corporate Update and Expected Date for Second Quarter Earnings Release
July 15, 2019 17:30 ET
|
Innovate Biopharmaceuticals, Inc
Innovate undertakes succession planning for a chief executive officer Finance team strengthened and well positioned for future growth Second quarter earnings release expected August 8, 2019 ...
Innovate Biopharmaceuticals Expands Its Management team with the Addition of Ed Sitar as Its Chief Financial Officer
June 24, 2019 07:00 ET
|
Innovate Biopharmaceuticals, Inc
RALEIGH, N.C., June 24, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and...
Innovate Biopharmaceuticals Announces the Start of the First Phase 3 Clinical Trial in Celiac Disease
June 10, 2019 08:01 ET
|
Innovate Biopharmaceuticals, Inc
RALEIGH, N.C., June 10, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and...
Innovate Biopharmaceuticals Announces Presentation of Three Posters Focusing on the Molecular Biology and Pharmacology of Larazotide at the 2019 Digestive Disease Week Conference in San Diego
May 20, 2019 09:45 ET
|
Innovate Biopharmaceuticals, Inc
Analyst Meeting to be held at 4:30pm ET today to discuss NASH data and provide clinical updates Three posters presented at DDW 2019 highlighted the protective effect and molecular mechanism of action...
Innovate Biopharma Announces Analyst Event on Monday, May 20, 2019, in San Diego
May 09, 2019 08:01 ET
|
Innovate Biopharmaceuticals, Inc
RALEIGH, N.C., May 09, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for...
Innovate Biopharmaceuticals Announces Closing of $8.7 Million Registered Direct Offering
May 01, 2019 16:30 ET
|
Innovate Biopharmaceuticals, Inc
RALEIGH, N.C., May 01, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) today announced the closing of its previously announced registered direct offering of 4,318,272...
Innovate Biopharmaceuticals Announces $8.7 Million Registered Direct Offering Priced At-the-Market
April 29, 2019 13:19 ET
|
Innovate Biopharmaceuticals, Inc
RALEIGH, N.C., April 29, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) today announced that it has entered into securities purchase agreements with certain institutional...
Innovate Biopharmaceuticals Shows Larazotide is the First Drug, with its Novel Mechanism of Action of Re-normalizing the Intestinal Barrier, to Demonstrate Improvements in validated NASH Biomarkers and Endpoints in synergy with obeticholic acid, an FXR agonist, and Reports key first quarter 2019 financial results and operational highlights
April 29, 2019 07:35 ET
|
Innovate Biopharmaceuticals, Inc
Continued execution toward start of the first phase 3 celiac disease clinical trial in the current quarter with key sites for trial launch selected and active recruitment efforts underway NASH Data...